Ryan L. Crass

Ryan L. Crass

Auto-generated profile, based on publicly available information

Ryan L. Crass

Ann Arbor Pharmacometrics Group, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
RCRyan L Crass
Ryan L Crass
KRKeith A Rodvold
Keith A Rodvold
BMBruce Mueller
Bruce Mueller
MPManjunath Pai
Manjunath Pai
Antibiotic renal dose adjustments are determined in subjects with stable chronic kidney disease and may not translate to patients in late phase trials and practice. Ceftolozane/tazobactam, ceftazidime/avibactam, and telavancin all carry precautionary statements for reduced clinical response in patients with baseline creatinine clearance 30 – 50 mL/min, potentially due to unnecessary dose reduction in the setting of acute kidney injury (AKI). In this review, we discuss the regulatory landscape for antibiotics eliminated by the kidney and highlight the importance of the first 48 hours of therapy. Using a clinical database, we identify AKI on admission in a substantial proportion of patients with pneumonia (27.1%), intra-abdominal (19.5%), urinary tract (20.0%), or skin and skin structure infections (9.7%) that resolved by 48 hours in 57.2% of cases. We suggest that deferred renal dose reduction of wide therapeutic index antibiotics could improve outcomes in patients with infectious diseases.

1 August 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RCRyan L. Crass
Ryan L. Crass
PCPier Giorgio Cojutti
Pier Giorgio Cojutti
MPManjunath Pai
Manjunath Pai
FPFederico Pea
Federico Pea
Linezolid is administered as a fixed dose to all patients despite evidence of increased exposure and myelosuppression in renal impairment. The objectives of these studies were to assess the risk of thrombocytopenia with standard-dose linezolid in renal impairment and to identify an alternate dosing strategy. In study 1, data from adult patients receiving linezolid for ≥10 days were retrospectively reviewed to determine the frequency of thrombocytopenia in patients with and without renal impairment. Time-to-event analyses were performed using Cox proportional-hazards models. In study 2, population pharmacokinetic modeling was employed to build covariate-structured models using an independent data set of linezolid concentrations obtained during routine therapeutic drug monitoring (TDM). Monte Carlo simulations were performed to identify linezolid dosing regimens that maximized attainment of therapeutic trough concentrations (2 to 8 mg/liter) across various renal-function groups. Toxicity analysis (study 1) included 341 patients, 133 (39.0%) with renal impairment. Thrombocytopenia occurred more frequently among patients with renal impairment (42.9% versus 16.8%; P < 0.001), and renal impairment was independently associated with this toxicity in multivariable analysis (adjusted hazard ratio [aHR], 2.37; 95% confidence interval [CI], 1.52 to 3.68). Pharmacokinetic analyses (study 2) included 1,309 linezolid concentrations from 603 adult patients. Age, body surface area, and estimated glomerular filtration rate (eGFR) were identified as covariates of linezolid clearance. Linezolid dose reductions improved the probability of achieving optimal exposures in simulated patients with eGFR values of <60 ml/min. Thrombocytopenia occurs more frequently in patients with renal impairment receiving standard linezolid doses. Linezolid dose reduction and trough-based TDM are predicted to mitigate this treatment-limiting toxicity.

27 December 2018 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
RCRyan L. Crass
Ryan L. Crass
MPManjunath Pai
Manjunath Pai

6 September 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
RCRyan L Crass
Ryan L Crass
RDRyan Dunn
Ryan Dunn
JHJoseph Hong
Joseph Hong
LKLynne C Krop
Lynne C Krop
MPManjunath Pai
Manjunath Pai
Vancomycin remains the mainstay of empirical therapy directed against MRSA. National guidelines recommend empirical dosing based on total body weight with trough-level therapeutic drug monitoring (TDM), which may not be optimal in obese and super obese patients. Furthermore, nomograms for empirical vancomycin dosing by estimated kidney function pre-date standardization of creatinine assays. To determine an empirical vancomycin dosing strategy for obese and super obese adults that is consistent with the AUC monitoring paradigm. We conducted a population pharmacokinetic study using data obtained from routine peak and trough TDM of vancomycin in obese and super obese adults. An empirical dosing nomogram was developed using Monte Carlo simulation to identify vancomycin doses that optimize the probability of efficacy and minimize the probability of acute kidney injury based on AUC. A total of 346 patients were included encompassing a wide range of body weight (69.6–293.6 kg) and BMI (30.1–85.7 kg/m2) values. In the final model, vancomycin clearance (CLV) was described using a linear combination of age, serum creatinine, sex and allometrically scaled body weight. Monte Carlo simulation demonstrated that maintenance doses >4500 mg/day were not required to achieve pharmacodynamic AUC targets in obese and super obese patients at clinically relevant values of CLV. Empirical vancomycin dosing informed by common clinical variables, including standardized creatinine, with subsequent individualization using AUC-targeted TDM can optimize therapy in obese and super obese adults.

1 April 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RCRyan L. Crass
Ryan L. Crass
WRW. Cliff Rutter
W. Cliff Rutter
DBDonna R. Burgess
Donna R. Burgess
CMCraig A. Martin
Craig A. Martin
DBDavid Burgess
David Burgess
Nephrotoxicity is the primary adverse effect of the polymyxins. The relative rates of toxicity of polymyxin B and colistin have not been fully elucidated, especially in patients with cystic fibrosis (CF). A retrospective cohort study of adults treated with polymyxin B or colistin for at least 48 h was conducted. The primary endpoint was the incidence of kidney injury assessed by RIFLE (i.e., r isk, i njury, f ailure, l oss, e nd-stage renal disease) criteria. Risk factors for kidney injury were evaluated using multivariate Cox regression. A total of 414 patients were evaluated, 220 of whom had CF. In patients without CF, there was no difference in kidney injury with polymyxin B and colistin (42.9% versus 50.3%, P = 0.46). Loop diuretic exposure was a risk factor for kidney injury (adjusted hazard ratio [aHR], 1.82; 95% confidence interval [CI], 1.16 to 2.83) in this population. In patients with CF, polymyxin B and colistin were associated with similar rates of kidney injury (34.5% versus 29.8%, P = 0.77). Diabetes (aHR, 2.68; 95% CI, 1.01 to 7.11), loop diuretics (aHR, 3.02; 95% CI, 1.36 to 6.73), and progressive care unit admission (aHR, 8.21; 95% CI, 2.55 to 26.46) were risk factors for kidney injury, while higher baseline serum creatinine levels (per 1 mg/dl) were protective (aHR, 0.08; 95% CI, 0.01 to 0.48). Total unadjusted kidney injury in polymyxin-treated patients was less frequent in those who had CF (30.5% versus 48.5%, P < 0.001). Polymyxin B and colistin are associated with a high incidence of kidney injury; cystic fibrosis may be protective against polymyxin nephrotoxicity, but further investigation is needed to confirm this conjecture.

21 April 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ESErnane Souza
Ernane Souza
RCRyan L. Crass
Ryan L. Crass
JFJeremy Felton
Jeremy Felton
KHKengo Hanaya
Kengo Hanaya
MPManjunath Pai
Manjunath Pai
In patients with renal impairment ( n = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations ( r 2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.